SCHEMBL19974119

SCHEMBL19974119

Cc1csc(NC(=O)C=CC(=O)O)n1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.59
ALDH1A1 P00352 5/20 0.59
MAPT P10636 4/20 0.59
HPGD P15428 4/20 0.59
PKM P14618 1/20 0.59
RAB9A P51151 8/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
NPC1 O15118 5/20 0.55
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.49
HTT P42858 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
HSD17B10 Q99714 1/20 0.48
RCE1 Q9Y256 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974118 1.00 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1MAPTHPGDPKM
SCHEMBL19981601 0.83 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1MAPTHPGDPKM
SCHEMBL19981418 0.81 MAPT (0.64) SMN1; SMN2ALDH1A1MAPTHPGDPKM
SCHEMBL1691061 0.81 MAPT (0.68) SMN1; SMN2ALDH1A1MAPTHPGDRAB9A
SCHEMBL19981604 0.80 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1MAPTHPGDPKM
SCHEMBL19974166 0.78 L3MBTL1 (0.46) SMN1; SMN2ALDH1A1MAPTHPGDPKM
SCHEMBL19974165 0.78 L3MBTL1 (0.46) SMN1; SMN2ALDH1A1MAPTHPGDPKM
SCHEMBL10816647 0.77 RAB9A (0.71) SMN1; SMN2ALDH1A1MAPTHPGDRAB9A
SCHEMBL11225467 0.76 MAPT (0.62) SMN1; SMN2ALDH1A1MAPTHPGDRAB9A
SCHEMBL19974141 0.76 PARP1 (0.76) SMN1; SMN2ALDH1A1MAPTHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512602-B1 INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF HSF PHARMACEUTICALS (CH) 2024-03-27 EP disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2021-07-22 US disclosed
EP-3512602-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF Pharmaceuticals (CH) 2019-07-24 EP disclosed
WO-2018050656-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF PHARMACEUTICALS (CH) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 SMN1; SMN2 4284/4885ALDH1A1 2641/4885MAPT 2930/4885
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 SMN1; SMN2 4284/4885ALDH1A1 2641/4885MAPT 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.